Evidence map›Paper›PMID 38993259›Full record

ArticleWorld journal of oncology2024

Use of Period Analysis to Timely Assess Five-Year Relative Survival for the Patients With Bone Cancer.

Xian Kuan Xie, Xiao Jiao Zhao, Run Hua Li, Yong Ran Cheng, Xin Bing, Jun Yang, Liang You Wang, Hui Jun Zhu, Tian Hui Chen, Jin Fei Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xian Kuan XieDepartment of Orthopedics, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310053, China.
Xiao Jiao ZhaoSchool of Public Health, Hangzhou Normal University, Hangzhou 311121, China.
Run Hua LiDepartment of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou 310022, China.
Yong Ran ChengSchool of Public Health, Hangzhou Medical College, Hangzhou 311399, China.
Xin BingSchool of Public Health, Hangzhou Normal University, Hangzhou 311121, China.
Jun YangSchool of Public Health, Hangzhou Normal University, Hangzhou 311121, China.
Liang You WangDepartment of Non-Communicable Chronic Disease Control and Prevention, Taizhou Municipal Center for Disease Control and Prevention, Taizhou 318000, Zhejiang Province, China.
Hui Jun ZhuCadre Health Center of Taizhou City, Taizhou 318000, Zhejiang Province, China.
Tian Hui ChenDepartment of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou 310022, China.
Jin Fei ChenThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: While timely assessment of long-term survival for patients with bone cancer is essential for evaluation on early detection and prognosis level of treatment of bone cancer, those data are extremely scarce in China. We aimed to timely and accurately assess long-term survival for patients with bone cancer in Eastern China. Methods: Patients diagnosed with bone cancer during 2004 - 2018 from four cancer registries with high-quality data from Taizhou, Eastern China were included. Five-year relative survival (RS) of bone cancer patients was calculated by period analysis for overall and the stratification. We further predicted 5-year RS during upcoming 2019 - 2023 using a model-based period analysis and survival data during 2004 - 2018. Results: Overall, 5-year RS for patients with bone cancer during 2014 - 2018 reached 46.6%, being 40.8% for male and 51.0% for female. Five-year RS declined along with aging, decreasing from 58.9% for age < 45 years to 41.5% for age > 60 years, while 5-year RS for urban area was higher compared to rural area (59.1% vs. 44.3%). The 5-year RS during upcoming 2019 - 2023 reached 48.3%. We found a clear upward trend in 5-year RS during 2004 - 2023 for overall and the stratification by sex, age at diagnosis, and region. Conclusions: We found that, for first time in China using period analysis, most up-to-date 5-year RS for patients with bone cancer reached 46.6% during 2014 - 2018, and is projected to reach 48.3% for the period 2019 - 2023, which has important implications for timely evaluation on early detection and prognosis level of treatment for patients with bone cancer in Eastern China.

Indexed as

Bone cancerCancer registryFive-year relative survivalPeriod analysis

Identifiers

PMID38993259
PMCPMC11236380

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.